Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Rennes – page 45

865 clinical trials in Rennes, France across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Rennes at a glance
865
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

865 trials in Rennes

Open in trial search

Muscle spasticity

Not recruiting

Comparing Abobotulinumtoxin A and Onabotulinumtoxin A for Adults with Upper Limb Spasticity

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Botulinum Toxin Type A
  • Sponsor:Ipsen Pharma

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Not recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Malignant melanoma

Not recruiting

Study of Acasunlimab Alone and Combined With Pembrolizumab in Patients With Advanced Skin Melanoma That Returned or Did Not Respond to Prior Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acasunlimab
  • Sponsor:Genmab A/S

Dermatitis atopic

Not recruiting

Study of Rocatinlimab with Topical Treatments for Adults with Moderate to Severe Atopic Dermatitis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Neoplasm

Not recruiting

Long-term study of dabrafenib and trametinib in children and adolescents with cancers that have V600 mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Dabrafenib Mesylate
  • Sponsor:Novartis Pharma AG

Triple negative breast cancer

Not recruiting

Study of Datopotamab Deruxtecan with or without Durvalumab compared to standard treatment for patients with Stage I-III triple-negative breast cancer who have remaining cancer after initial therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Gastric cancer

Not recruiting

Study of FOLFIRI with Domvanalimab and Zimberelimab in patients with advanced gastric or gastro-esophageal junction cancer who progressed after chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Domvanalimab
  • Sponsor:Fondation Franc.Cancerologie Digestive

Ovarian cancer

Not recruiting

Evaluation of COM701 as Maintenance Therapy for Patients with Relapsed Platinum-Sensitive Ovarian Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Saline
  • Sponsor:Compugen Ltd.

Idiopathic pulmonary fibrosis

Not recruiting

Study on the Effects of CAL101 for Patients with Idiopathic Pulmonary Fibrosis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:CAL101
  • Sponsor:Calluna Pharma AS

Squamous cell carcinoma of head and neck

Not recruiting

Study of Pucotenlimab with Becotatug Vedotin versus Becotatug Vedotin alone for patients with locally advanced head and neck squamous cell carcinoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:PUCOTENLIMAB
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Cardiac amyloidosis

Not recruiting

Study on the Effects and Safety of ALXN2220 for Adults with Transthyretin Amyloid Cardiomyopathy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Alxn2220
  • Sponsor:Neurimmune AG

Small cell lung cancer

Not recruiting

Study of Tarlatamab Treatment in Patients with Small Cell Lung Cancer: Evaluation of Different Dosing Schedules

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Siltuximab
  • Sponsor:Amgen Inc.

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Rennes

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on head and neck cancers, breast cancer, and hematologic malignancies. Studies are evaluating novel therapeutic approaches including immunotherapy combinations and targeted treatments.

  • Advanced squamous cell carcinoma treatments
  • Triple-negative breast cancer interventions
  • Acute myeloid leukemia therapies

Multiple research centers are investigating breakthrough treatments for various stages of cancer progression.

02 Neurological Disorders

Comprehensive research into multiple sclerosis and movement disorders, utilizing advanced imaging techniques and innovative therapeutic approaches.

  • MS treatment optimization
  • Essential tremor management
  • Neuroinflammation imaging

Studies are focused on improving patient outcomes through targeted interventions and precision medicine approaches.

03 Critical Care Medicine

Investigating new approaches in postoperative care and immunotherapy for critical care patients, with emphasis on patient comfort and infection prevention.

  • Pain management protocols
  • Immune system modulation
  • Post-surgical care optimization

Research aims to enhance recovery outcomes and reduce complications in intensive care settings.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.